Search results
Showing 1216 to 1230 of 1335 results for primary care
Discontinued [GID-TAG368]
Sirukumab for previously treated moderate to severe active rheumatoid arthritis (ID1002)
Discontinued [GID-TA10180]
Zanubrutinib for treating Waldenstrom's macroglobulinaemia (TA833)
Evidence-based recommendations on zanubrutinib (Brukinsa) for treating Waldenstrom’s macroglobulinaemia in adults.
Tocilizumab for the treatment of rheumatoid arthritis (TA247)
Evidence-based recommendations on tocilizumab (RoActemra) for treating rheumatoid arthritis in adults.
Ekso exoskeleton for rehabilitation in people with neurological weakness or paralysis (MIB93)
NICE has developed a medtech innovation briefing (MIB) on the Ekso exoskeleton for rehabilitation in people with neurological weakness or paralysis .
Evidence-based recommendations on the EOS 2D/3D imaging system for producing 2D and 3D images of the skeleton
Evidence-based recommendations on ustekinumab (Stelara) for treating active psoriatic arthritis in adults.
This guideline covers how to improve the physical environment to encourage and support physical activity. The aim is to increase the general population’s physical activity levels.
This guideline covers road-traffic-related air pollution and its links to ill health. It aims to improve air quality and so prevent a range of health conditions and deaths.
Apalutamide for treating non-metastatic, hormone-relapsed prostate cancer [ID1174]
Discontinued [GID-TA10377]
Molecular testing strategies for Lynch syndrome in people with colorectal cancer (DG27)
Evidence-based recommendations on using immunohistochemistry or microsatellite instability testing to guide further testing for Lynch syndrome in people with colorectal cancer
Arimoclomol for treating Niemann-Pick disease Type C [ID1312]
In development [GID-HST10037] Expected publication date: TBC
Dapagliflozin in combination therapy for treating type 2 diabetes (TA288)
Evidence-based recommendations on dapagliflozin (Forxiga) given with other drugs for treating type 2 diabetes in adults.
More people are benefitting from NICE-recommended statins to reduce heart attacks and strokes
Around 5.3 million people in England were given a NICE-recommended statin or ezetimibe by their GP to help reduce their cholesterol during 2023/24, the largest number on record and almost 900,000 more than in 2022/23.